Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study

Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study Eur J Clin Pharmacol (2017) 73:1187–1194 DOI 10.1007/s00228-017-2288-1 PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study 1 1 1 1 Nazanin Abolhassani & Julien Castioni & Pedro Marques-Vidal & Peter Vollenweider & Gérard Waeber Received: 5 April 2017 /Accepted: 12 June 2017 /Published online: 21 June 2017 Springer-Verlag GmbH Germany 2017 Abstract obesity, smoking, previously diagnosed hypertension, or dia- Objectives This study aimed to assess the prevalence, the betes or dyslipidemia were significantly and independently change, and the determinants of change in polypharmacy in associated with initiating and maintaining polypharmacy. a population-based sample. Conclusion In a population-based sample, prevalence of Methods Baseline (2003–2006) and follow-up (2009–2012) polypharmacy doubled over a 5.6-year period. The main de- data are from 4679 participants aged between 35 and 75 years terminants of initiating polypharmacy were age, overweight (53.5% women, mean age 52.6 ± 10.6 years) from the popu- and obesity, smoking status, and previously diagnosed cardio- lation of Lausanne, Switzerland. Polypharmacy was defined vascular risk factors. by the regular use of ≥5 drugs.Four categoriesofchangewere defined: never (no polypharmacy at baseline and follow-up), . . . Keywords Polypharmacy Determinants Trends General initiating (no polypharmacy at baseline but http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study

Loading next page...
 
/lp/springer_journal/determinants-of-change-in-polypharmacy-status-in-switzerland-the-4ntitz2OuO
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-017-2288-1
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial